Traws Pharma
TRAW
28 hedge funds and large institutions have $6.62M invested in Traws Pharma in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
71% more capital invested
Capital invested by funds: $3.86M → $6.62M (+$2.76M)
27% more funds holding
Funds holding: 22 → 28 (+6)
2.52% more ownership
Funds ownership: 42.78% → 45.3% (+2.5%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$784K |
| 2 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$115K |
| 3 |
Jane Street
New York
|
+$39.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$379K |
| 2 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
-$55.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$47.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
TRAW Hedge Fund Activity: Q1 2026 in Review
28 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2026, worth a combined $6.62M — up 71% from $3.86M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TRAW positions and 7 closed out — a net gain of 7 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $784K. The largest seller was Squadron Capital Management, cutting an estimated $379K.
- 28 institutional investors held Traws Pharma (TRAW) as of Q1 2026, up from 22 in Q4 2025.
- Funds reported $6.62M of Traws Pharma stock for Q1 2026, up 71% quarter-over-quarter.
- 14 funds opened new Traws Pharma positions in Q1 2026 and 7 closed out, a net change of +7 holders.
- The largest Traws Pharma buyer in Q1 2026 was Dauntless Investment Group, an estimated $784K added.
- The largest Traws Pharma seller in Q1 2026 was Squadron Capital Management, an estimated $379K sold.
Based on aggregated 13F filings for Q1 2026.